The division of Synektik is complete – the court has registeredthe issue of Syn2bio shares

On 27 March 2026 the registry court entered in the National Court Register the increase in Syn2bio’s share capital connected with the issue of demerger shares for Synektik shareholders. This marks the formal completion of the process of dividing Synektik into two separate entities. Consequently, alongside Synektik, which is already a listed company, on or about 16 April 2026 will be the debut on the Warsaw Stock Exchange of the shares of Syn2bio, the company to which Synektik has spun off the business connected with cardiotracer research and future commercialization of this innovative radiopharmaceutical for diagnosis of heart disease.

“The division of Synektik is now a fact,” said Cezary Kozanecki, founder and CEO of Synektik and CEO of Syn2bio. “We have spun off to Syn2bio the business connected with development of the cardiotracer, our flagship R&D project. Syn2bio has secured funds for continuing clinical trials for another 12–14 months.” Touching on the concept behind the division, the CEO explained: “Syn2bio will also be able to seek financing from grants, subsidies and programmes intended for SMEs, which were no longer accessible for Synektik as a large enterprise. In turn, Synektik, which previously financed the research costs, will gain space for further improvement in its profitability and increased distribution of dividends.”

Cezary Kozanecki added: “Thanks to the division, there will soon be two independent companies listed on the WSE, with different operating profiles, attracting investors with different appetites for risk and different expectations. This will enable a more appropriate valuation of both companies, better reflecting their potential and directions for growth. I believe that over the longer term, this should translate into an increase in the value of both companies’ shares.”

The final stretch before Syn2bio’s listing on the WSE

The increase in Syn2bio’s share capital registered by the court is connected with the issue of a total of 8,529,129 Syn2bio shares (the share capital of Synektik is currently divided into the same number of shares). The Syn2bio shares will be allocated to Synektik shareholders in a 1:1 ratio—for each Synektik share held on the record date, the investor will receive one share of Syn2bio. This will occur automatically, without the need for shareholders to take any additional action.

It is the company’s intention for the record date to be set at 7 April 2026. Under this scenario, the stock-market trading session on 1 April (i.e. two trading days before the record date) will be the last session when it is possible to acquire Synektik shares entitling the holder to participate in the division. This also means that the reference share price for the following session (2 April) will be reduced by the value of the business spun off to Syn2bio, or about 7.73% (this proportion results from the valuation previously prepared for the purposes of the division plan, as of 30 June 2025). This value will also constitute the reference price for the first session of listing of Syn2bio shares on the WSE. According to the adopted timetable, the stock-market debut of Syn2bio is expected to occur on or about 16 April 2026. The day before, the Syn2bio shares will appear in the shareholders’ accounts.

The main business of Syn2bio will be the continued development and commercialization of the cardiotracer project, and in the future also seeking innovative new pharmaceutical compounds. The other business currently conducted by Synektik will remain within that company. It will thus continue to handle such matters as distribution and servicing of innovative medical equipment, development of its own IT solutions, and production and sale of radiopharmaceuticals.

Anticipated timetable for the public offering of Syn2bio shares – further steps

***

About the Synektik Group

The Synektik Group is a leading producer of advanced radiopharmaceuticals and IT solutions (including the Zbadani.pl medical platform and SynDose dose-monitoring app), a provider of specialist service and measurement support, and a distributor of innovative medical devices used in diagnostics and therapy across radiology, oncology, cardiology and neurology.

In medical-device distribution, the company works with a broad line-up of global manufacturers of diagnostic and therapeutic products and, on the strength of this portfolio and its expertise, delivers, among other things, hybrid operating theatres on a turnkey basis.

Synektik is the exclusive distributor in Poland, Czechia, Slovakia, Lithuania, Latvia, Estonia and Ukraine of da Vinci robotic systems for minimally invasive surgery, the exclusive distributor on these markets (except for Ukraine) of Symani robots for micro- and supermicrosurgery and Edison systems for non-invasive removal of soft-tissue tumours, and the exclusive distributor in Poland, Czechia and Slovakia of non-invasive neurosurgery systems using ultrasound (the MRgFUS technology for treatment of essential tremor and Parkinson’s disease-related tremor).

Synektik operates three radiopharmaceutical production facilities in Poland, one of which also serves as an R&D centre for developing innovative new products with applications in oncology, cardiology and neurology. The group is also developing its own clinical research centre. The company’s flagship development project is a cardiotracer—an innovative radiopharmaceutical with global potential in coronary artery disease diagnostics, currently in clinical trials. The company is also the leading supplier in Poland of specialized radiopharmaceuticals used, among other things, in diagnosing hepatocellular carcinoma and prostate cancer and its bone metastases.

In the most recent financial year (1 October 2024 – 30 September 2025), the Synektik Group generated sales revenue of nearly PLN 682 million (+9% y/y), achieved adjusted EBITDA of almost PLN 178 million (+24% y/y), and earned a net profit of close to PLN 103 million (+25% y/y).

For more information visit www.synektik.pl

***

Contact:

NBS Communications

e-mail: synektik@nbs.com.pl

Piotr Wojtaszek | +48 500 202 355

Krzysztof Woch | + 48 516 173 691

Maciej Szczepaniak | +48 514 985 845

MakMedia Group

Błażej Dowgielski | +48 692 823 744

e-mail: b.dowgielski@makmedia.pl

Legal disclaimer

This material and the information contained herein are for informational purposes only and should not constitute a basis for making decision to purchase or subscribe for shares in Syn2bio S.A. with its registered office in Warsaw (“Company”).

The only legally binding documents containing information about the Company, the Company’s securities, the public offering and the admission and introduction of the Company’s shares to trading on the regulated market operated by Warsaw Stock Exchange S.A. (“GPW”) is Company’s prospectus prepared in accordance with the European Parliament and of the Council Regulation (EU) 2017/1129 of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (Office Journal of the European Union of 2017, No 168, pp. 12, as amended) (“Prospectus Regulation”), approved by Financial Supervision Authority (“KNF”) on 12 March 2026 (“Prospectus”) together with any supplements and updates.

For the purposes of the offer and the admission and introduction of the Company’s securities to trading on the regulated market operated by the GPW, the Prospectus has been published and made available on the Company’s website (www.syn2bio.pl) and, additionally, for information purposes only, on the website of the investment firm (www.mdm.pl/bm/nowe-emisje).

KNF approves Prospectus solely as meeting the standards of completeness, intelligibility and consistency imposed by the Prospectus Regulation. Approval of the Prospectus should not be understood as approval of the Company or the quality of the securities that are the subject of the Prospectus. In approving the Prospectus, KNF does not verify or approve the Company’s business model, methods of conducting business or methods of financing. In the proceedings for the approval of the Prospectus, the accuracy of the information contained in the Prospectus, the level of risk associated with the Company’s operations, or the investment risk associated with the acquisition of the Company’s securities are not assessed. Investors should make their own assessment of the adequacy of investing in the shares offered on the basis of the Prospectus.

Under no circumstances does the information contained in this press release constitute a prospectus or any other offering document within the meaning of generally applicable law, including the Prospectus Regulation or the Act of 29 July 2005 on Public Offerings, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies (i.e. Journal of Laws of 2025, item 592). Prospectus may contain information that differs from the information contained in this press release. This press release is for informational purposes only and the information contained herein may not be considered complete or comprehensive. Neither this press release nor any part thereof, nor the fact of its distribution, constitutes a basis for or may be relied upon in connection with any agreement, commitment or investment decision.

This press release and the information contained herein are not intended for direct or indirect distribution or use in any jurisdiction where such distribution or use would be contrary to local laws or other regulations, or which would subject the Company or the Company’s shareholders or any of their affiliates to authorization, notification, licensing or other requirements under the relevant laws of the United States of America, Australia, Canada and Japan or among residents of those countries.

This material does not constitute an investment recommendation within the meaning of Regulation on market abuse (Regulation (EU) No 596/2014) and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 complementing regulation on market abuse with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.

The distribution of this press release and other information contained herein may be restricted by law, and persons who come into possession of any document or other information referred to in this press release should inform themselves about and observe any such restrictions. Failure to comply with these restrictions may constitute a violation of securities laws in a particular jurisdiction. In certain jurisdictions, the distribution of this press release may be unlawful. The Prospectus and the Company’s securities covered by it have not been and will not be registered, approved or notified in any country outside the Republic of Poland, in particular in accordance with the provisions of the Prospectus Regulation or the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold outside the Republic of Poland, unless such offer or sale could be made in a given country in accordance with the law, without the need for the Company, shareholders or any of their affiliates and their advisors. In particular, this announcement does not constitute an offer of securities for sale in the United States of America. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act and may not be offered or sold in the United States of America, unless as an exception to the registration requirements of the U.S. Securities Act or in a transaction not subject to the registration requirements of the U.S. Securities Act. No public offering of the Company’s securities will be made in the United States of America.

It may be unlawful to distribute this press release to entities or persons subject to legal or regulatory restrictions (including, but not limited to Council Regulation (EU) No 833/2014 of 31 July 2014 concerning restrictive measures in view of Russia’s actions destabilizing the situation in Ukraine and in Council Regulation (EC) No 765/2006 of 18 May 2006 concerning restrictive measures in view of the situation in Belarus and Belarus’s involvement in Russia’s aggression against Ukraine) concerning economic, financial or trade sanctions, embargoes or other restrictive measures adopted or enforced by (i) the European Union, including its Member States, (ii) the United Kingdom of Great Britain, (iii) Switzerland, (iv) the United States of America, (v) the United Nations, and (vi) relevant government agencies and bodies, including, but not limited to, the Office of Foreign Assets Control (OFAC) of the U.S. Department of the Treasury, the U.S. Department of State, the U.S. Department of Commerce, and His Majesty’s Treasury, covering the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic, Cuba, Iran, North Korea, Syria, Russia, Belarus, Sudan and South Sudan.